Najib Ben Khaled

Clinician Scientist @LMU University Hospital and @TumTransla in Roland Rad lab, focused on HPB cancers and liver disease

[Najib Ben Khaled @N_BenKhaled]

Great to see our new study on a vulnerable phase in HCC immunotherapy highlighted. Thank you @Erman_Akkus, and thanks to all collaborators!

[Erman Akkus @Erman_Akkus]

🏥Early mortality in atezo-beva for HCC
@JHEP_Reports

🚨CPS B and high CRP ➡️ early mortality (90days)
❗️Among patients with CPS B: B9, ECOG ≥2, high creatinin

👉https://t.co/VHQUU5gQmZ

#cancer #oncology #MedX #liver @OncoAlert

[Najib Ben Khaled @N_BenKhaled]

Join the Digestive Disease Mechanism Summit #uegweek to explore the fundamental research shaping the future of gastroenterology!

[United European Gastroenterology @my_ueg]

Tomorrow our first DDM Summit starts! 🎉

This new format is designed for basic scientists, offering a 3-day programme dedicated to the Pathogenesis of GI tract diseases (including cancer).

📍 Join us onsite in Room New York!

🔗 https://t.co/eeaEASqp6E

#UEGWeek

[Najib Ben Khaled @N_BenKhaled]

@imsmart420 @Erman_Akkus @SuyogCancer @SABCSSanAntonio @DrYukselUrun @OncBrothers @santhoshak23220 @sitcancer @ImmunotherapyFd Thank you! Can you please post the link to the respective esc guideline?

[Dr. Foxpaws Fauxpas @foxpaws_onco]

ICI induced myocarditis ❤️‍🔥
🔬 Patho (EMBx) - Dallas Cx
Multifocal inflammatory infiltrates + overt cardiomyocyte loss

⚕️Clinical
cTn - new/significant ⬆️⬆️ from baseline
- with 1 major/2 minor criteria
- Exclude ACS/acute infectious myocarditis

@SuyogCancer @SABCSSanAntonio

[Najib Ben Khaled @N_BenKhaled]

Which score to use for prognosis prediction in HCC treated with IO?🤔
@SJGairing , @DrFFoerster & team developed CABLE and compared to ALBI & others.
Read @JHEP_Reports
https://t.co/EEpeDPssT8
Try the score: https://t.co/fDvQgcQ13k
Happy to have contributed.
#livertwitter

[Najib Ben Khaled @N_BenKhaled]

Looking forward to a great @GASLtweets congress, talk from @BenniRuf @GallageSuchira @duell_miriam and many more! #GASL25

[Najib Ben Khaled @N_BenKhaled]

Must-read for GI oncologists!

Valuable insights into outcome and management of HCC patients with complete response following IO by @BernharScheiner et al.

Honored to have contributed.

[HEPATOLOGY Journal @HEP_Journal]

Original Article
Outcome and management of patients with hepatocellular carcinoma who achieved complete response to immunotherapy-based systemic therapy

Scheiner et al.
#LiverX
https://t.co/uMMVd2fC0O

[Arndt Vogel @ArndtVogel]

Liver Cancer in 2021: Global Burden of Disease Study
@JHepatology
https://t.co/iFmNgJQqXW
👉2021: 529.202 cases & 483.875
👉25% increased in deaths since 2010
👉HBV- & HCV-HCC⬇️, alcohol stable, MASLD⬆️
@myESMO @EASLnews @ILCAnews #livertwitter

[Najib Ben Khaled @N_BenKhaled]

Join us in advancing liver health! @ArndtVogel

[Richard Van Noorden @Richvn]

“I can eat sugar now".
25-yr-old woman w/ type 1 diabetes produces her own insulin after a transplant of reprogrammed stem cells (extracted from her own body). Follows similar type 2 diabetes success.
by @SmritiMallapaty | @Nature
https://t.co/a3Ok8rNbHj

[JHEP Reports @JHEP_Reports]

❕Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events

🔓#OpenAccess at 👉 https://t.co/ctEZz6YNfh

#LiverTwitter
#HCC

[Arndt Vogel @ArndtVogel]

Keynote lecture: Ten years of improvement in the treatment of liver cancer #ESMOGI24
👉Amazing development, multiple 💊available in 2024
👉Redefining "cure" & role of LRT > early adaptation/switch
👉more to come: CAR-T cells, new💊, Proton Tx..
@myESMO #ESMOAmbassadors

[Arndt Vogel @ArndtVogel]

🔥news from #EASL2024
Outcome of pts with HCC who achieved a complete response to ICI-based therapy
👉🗺️RWD, 174/3933 pts
👉mRFS 30 mo, 3yr OS 87%
😅Great to report recurrence free survival (!) after systemic therapy in advanced HCC
@myESMO @EASLedu @ILCAnews #livertwitter

[Najib Ben Khaled @N_BenKhaled]

@JohannvonFelden @EASLedu @EASLnews Amazing work, congratulations!

[Arndt Vogel @ArndtVogel]

🔥off the press: Durvalumab plus GemCis in advanced biliary tract cancer: TOPAZ-1 phs-3
@LancetGastroHep
🧐Updated OS data, including long-term survivors & OS by ORR
👇my personal Share Link:
https://t.co/bVHUSPymS2
@myESMO @EASLnews @ILCAnews @curecc #livertwitter

[Najib Ben Khaled @N_BenKhaled]

Link to the full text:
https://t.co/Zr2o6ov4AK

[Najib Ben Khaled @N_BenKhaled]

Read our paper in @JHEP_Reports on the risk of bleeding and thromboembolism in atezobev vs lenvatinib for HCC. Big thanks to the fantastic collaborators!

[GI Oncology Now @GiOncNow]

🩸 As treatment with atezolizumab/bevacizumab and lenvatinib for HCC may cause an increased risk of bleeding, a study by @N_BenKhaled and colleagues analyzed the efficacy and safety of each treatment in a real-world population.

Learn more: https://t.co/yNIWrF6qjg

#LiverCancer

[Najib Ben Khaled @N_BenKhaled]

https://t.co/pba79Io0FJ

[United European Gastroenterology @my_ueg]

📢 Final call: Only 2 days left to apply for the @uegjournal Trainee Editor position!
Apply by May 16, 2024 and enhance your career with UEG! https://t.co/aUUvWrfvQf

#myUEGcommunity #weareUEG #UEGJ

[United European Gastroenterology @my_ueg]

Since 2000, Europe has seen a worrying increase in digestive diseases and cancer cases 📈

Dive into our country-specific factsheets for insights and recommended actions to combat this rise in your country 🔎 👉 https://t.co/X22A33oQ79 #DigestiveHealthMonth

[Algül Lab @AlgulLab]

Algül Lab is hiring a new postdoctoral researcher! If you are excited to work in the pancreatic cancer field under the funded BMBF consortium, we are looking forward to seeing your applications! Please spread the word!😊#pancreaticcancer #postdoc
https://t.co/CgUqDpMDRv